Periostin and closing volume in combined pulmonary fibrosis and emphysema

Fernando Medeiros Anselmo (fernandomanselmo@hotmail.com)
Universidade do Estado do Rio de Janeiro - Campus Vila Isabel
https://orcid.org/0000-0001-9178-5787

Cláudia Henrique da Costa
Universidade do Estado do Rio de Janeiro

Luciana Silva Rodrigues
Universidade do Estado do Rio de Janeiro

Thaís Porto Amadeu
Universidade do Estado do Rio de Janeiro

Mariana Martins de Athaide
Instituto Oswaldo Cruz

Mônica Cristina Brandão dos Santos Lima
Universidade do Estado do Rio de Janeiro

Luana Fortes Faria
Universidade do Estado do Rio de Janeiro

Thaís Ferrari da Cruz
Universidade do Estado do Rio de Janeiro

Agnaldo José Lopes
Universidade do Estado do Rio de Janeiro

Rogerio Lopes Rufino
Universidade do Estado do Rio de Janeiro

Research article

Keywords: CPFE, Emphysema, IPF, Nitrogen washout test, periostin

DOI: https://doi.org/10.21203/rs.3.rs-21514/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background

Combined pulmonary fibrosis and emphysema (CPFE) is an entity characterized by the presence of emphysema in upper lobes and fibrosis in lower lobes. Due to the presence of the two diseases concomitantly, it may be difficult to diagnose. This study aims at a better understanding of this entity and proposes biological markers (functional and biochemical) that help in this characterization.

Methods

A prospective, observational, cross-sectional study was carried out at a reference center. Pulmonary function tests (spirometry, CO-diffusion capacity, plethysmography and single-maneuver nitrogen washout test - SBWN 2 ) and biochemical markers (periostin, mucin-16, PDGF-BB and TGF-β 1 ) were measured in groups of patients: idiopathic pulmonary fibrosis, CPFE and chronic obstructive pulmonary disease (COPD).

Results

Variables derived from SBWN 2 - closing volume (CV) / vital capacity (VC) (%) and closing capacity (CC) / total lung capacity (TLC) (%) - were found to be higher in the CPFE group compared to the Idiopathic pulmonary fibrosis (IPF) group (CV/VC%: 0.25 (0.12 – 11.01) and 13.05 (0.21 – 20.73); p = 0.005; CC/TLC%: 30.1 (22.4 – 37.47) and 33.69 (32.05 – 41.98); p = 0.03, respectively). Periostin was higher in the CPFE group than in the other groups [CPFE: 66.74 (45.21 – 90.5), IPF: 43.81 (31.97 – 56.18), COPD: 40.08 (20.66 – 50.81); p = 0.0002], and mucin-16 was higher in the IPF group than in the CPFE group [CPFE: 13.59 (4.16 – 28.16); IPF: 71.94 (40.46 - 164); COPD: 25.85 (9.27 – 30.29); p = 0.02].

Conclusions

Findings show that CPFE presents different functional and biochemical characteristics than IPF, including higher CV/VC%, CC/TLC% and periostin, whereas mucin-16 was higher in the IPF.

Introduction

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease characterized by progressive interstitial fibrosis of unknown cause. Some patients, typically those with a high smoking load, develop combined pulmonary fibrosis and emphysema (CPFE). Due to the distinct clinical, functional and radiological characteristics, CPFE has been described as a syndrome. These distinct characteristics increase the risk of developing pulmonary hypertension and lung cancer, thus resulting in a worse prognosis. Therefore, it is important that differential diagnosis be performed properly and early. Nevertheless, there is no specific therapy for CPFE.
Identifying new biological markers may facilitate the diagnosis and follow-up of patients with CPFE. Spirometry cannot effectively differentiate these patients because the coexistence of two antagonistic diseases can alter the test results and lead to underestimation of disease severity. Currently, techniques such as the nitrogen washout test have become widely used in the clinical environment.

Although the nitrogen washout test was developed approximately 60 years ago, modern software is currently used with this technique. Traditionally, the examination can be conducted for single or multiple breaths.\(^4\) The nitrogen washout test reveals the heterogeneity in the distribution of pulmonary ventilation and has been used to evaluate small airways in patients with obstructive diseases.\(^5,6\) However, no studies have evaluated the use of this method for evaluating CPFE or IPF.

While clinical-functional evaluation is important for the diagnosis and follow-up of patients with CPFE, a serum biomarker useful for diagnosis and prognosis prediction is needed. There are no accepted serum biomarkers for IPF or CPFE. Some biomarkers such as periostin have been tested and show potential.\(^6^–^8\) Other molecules that are part of the fibrogenesis cascade, such as transforming growth factor (TGF)-\(\beta_1\) and platelet-derived growth factor-BB (PDGF-BB), have also been examined.\(^9^–^11\) Additionally, mucin–16 (MUC–16 or CA–125) has been associated with increased mortality in patients with IPF and also with the development of lung cancer in patients with interstitial lung diseases.\(^12,13\)

Thus, this study aimed was conducted to evaluate patients with CPFE, particularly through functional assessment, and identify a possible serum biomarker for facilitating differential diagnosis.

**Methods**

This prospective, observational, cross-sectional study was carried out with approval from the Research Ethics Committee. All patients signed informed consent forms before participating in this study.

Patients with IPF, CPFE, and chronic obstructive pulmonary disease (COPD) were selected. The diagnosis of IPF was based on the criteria of the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Association 2011.\(^14\) All selected patients showed consistent clinical presentation and a tomographic pattern of usual interstitial pneumonia (UIP). The diagnosis of CPFE was based on the original report by Cottin et al.\(^2\) as a syndrome characterized by upper lobe emphysema (well-demarcated areas of decreased attenuation with very thin wall (<1 mm) or no wall) and pulmonary fibrosis of the lower lobes (presence of features consistent with usual interstitial pneumonia) according to high resolution chest CT (HRCT). All cases of interstitial lung disease (IPF and CPFE) were confirmed by a multidisciplinary team and patients with collagen vascular disease, hypersensitivity pneumonia or other interstitial lung disease (ILD) were excluded. We chose to include only patients with a firm diagnosis of IPF and CPFE in order to avoid bias due to inclusion of patients with other type of interstitial lung diseases with different prognosis. All tests performed in the IPF and CPFE groups were obtained before patients started anti-fibrotic therapy.
Patients with chronic obstructive pulmonary disorder (COPD) were diagnosed according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017. COPD patients with emphysema phenotype were selected based on clinical and functional features (patients with < 2 exacerbations/year and carbon monoxide diffusion capacity <50%). Patients with other respiratory diseases such as asthma, bronchiectasis, and severe neuromuscular diseases that could alter lung function were excluded. Patients who were in infectious exacerbation at the time of selection were included only 3 months after clinical improvement.

All patients were interviewed by the examiner, after which peripheral blood samples were collected to measure periostin, mucin–16, PDGF-BB, and human TGF-β1 and for functional evaluation (spirometry, measurement of the carbon monoxide diffusion capacity (DLco) and transfer coefficient (Kco), plethysmography of whole body, and single-breath nitrogen washout test).

All tests were performed by a single operator and with the same equipment, HD CPL (nSpire Health Inc., Longmont, CO, USA) and followed American Thoracic Society standardization. Knudson’s equations for spirometry and Neder’s equations were used to determine static pulmonary volumes, carbon monoxide diffusion capacity, and the transfer factor. The single-breath nitrogen washout test was performed (SBWN2) using the HD PFR 3000 apparatus (nSpireHealth, Inc.). The single-breath maneuver washout was performed according to the recommendations of the American Thoracic Society/European Respiratory Society and analysed using Buist equations.

The concentration level of each biomarker in the sera of patients was determined with enzyme-linked immunosorbent assay (ELISA) kits for periostin (DuoSet ELISA; R&D Systems, Minneapolis, MN, USA; 1:50 dilution), mucin–16 (Thermo Fisher Scientific, Waltham, MA, USA; 1:2 dilution), PDGF-BB (Peprotech, Rocky Hill, NJ, USA; 1:10 dilution), and TGF-β1 (Affymetrix, eBioscience, San Diego, CA, USA; 1:10 dilution). The sensitivities of the ELISA kits were 62.5 pg/mL for periostin, 1 U/mL for mucin–16, 32 pg/mL for PDGF-BB, and 8 pg/mL for TGF-β1. All ELISAs were performed according to the manufacturer’s instructions. ELISAs were read in an automated microplate reader (Multiskan FC; Thermo Fisher Scientific).

Determination of statistical significance and graph preparation were conducted using GraphPad Prism version 8.0 software (GraphPad, Inc., La Jolla, CA, USA). The D’Agostino and Pearson test were used to evaluate the normal distribution of the samples. Analysis of variance, Kruskal Wallis test, and Dunn’ post hoc were used to differentiate groups. Differences were considered significant when the p value was less than 0.05.

Results

A flow diagram design is shown in Figure 1. The ages of patients in the three groups (IPF, CPFE, and COPD) and the degree of dyspnea as assessed by the modified Medical Research Council scale did not significantly differ between groups. However, there was a significant difference in smoking load among
the three groups; COPD patients showed the highest smoking load (Table 1). Turkey’s post-test analysis showed that the smoking load in the CPFE group was significantly higher than in the IPF group.

Functional analysis of the three groups revealed a significant difference in many of the parameters studied. Statistically significant values of forced expiratory volume in the first second (FEV<sub>1</sub>), DLco, Kco, residual volume (RV)/total lung capacity (TLC), and TLC (%) were observed in the CPFE group compared to in the COPD group. However, no significant differences were observed between the IPF group and CPFE group (Table 1). The parameters evaluated by SBW<sub>2</sub>, phase III slope (SIII), and ΔN<sub>2</sub> 750–1250mL presented values above the normal range in all groups, but the differences were not significant. However, the closing volume (CV)/vital capacity (VC) (%) and closing capacity (CC)/TLC (%) ratios were significantly higher in individuals with CPFE than in those with IPF (p = 0.005 and p = 0.03, respectively, according to Turkey’s post-test). These data are presented in Table 2.

In the analysis of serum biomarkers, according to Table 3, periostin showed significantly higher values in the CPFE group than in the other two groups [CPFE: 66.74 (45.21—90.5); IPF: 43.81 (31.97—56.18); COPD: 40.08 (20.66—50.81); p = 0.0002]. Turkey’s post-test shows that mucin–16 levels were significantly higher in the IPF group than in the CPFE group (p = 0.02) and were higher than in the COPD group (p = 0.058).

The Figures 2, 3, 4 and 5 show the comparison between all the serum biomarkers studied between the 3 groups of patients, demonstrating the statistically significant relationship with periostin and mucin–16 in their respective groups.

**Discussion**

Previous studies suggested that patients with CPFE form a subgroup of IPF or have a different disease, as they present with different clinical, radiological and functional alterations than patients with IPF. Isolating this group of patients can facilitate diagnosis and enable early treatment. Evaluating CPFE in a study series is difficult because many patients with various types of interstitial diseases are included, such as patients with connective tissue diseases, particularly rheumatoid arthritis and non-specific fibrotic interstitial pneumonia. The inclusion of several standards makes it difficult to assess prognosis. We included only patients with a well-established UIP pattern and identified important differences from a functional perspective and in blood biomarker profiles. In the blood samples, patients with CPFE had higher levels of periostin while patients with IPF had higher levels of mucin–16. Functionally, CV/VC (%) and CC/TLC (%) were higher in patients with CPFE than in those with IPF, suggesting increased air trapping associated with emphysema.

The smoking history was common in the three groups, while the smoking load was significantly higher in the COPD group compared to the other groups and higher in the CPFE group than in the IPF group. Patients with CPFE are typically smokers or former smokers with a history of smoking over 40 packets per year. This suggests a minimum smoking load leading to progression of the combined disease.
However, CPFE has been reported in patients with no smoking history, suggesting that there is a genetic predisposition for the development of the syndrome.\textsuperscript{24}

As in previous studies, differentiating between IPF and CPFE by spirometry was difficult.\textsuperscript{2,26} Patients with CPFE showed flow measurements close to those with IPF and volume measurements close to those in patients with COPD. No spirometric variable could differentiate CPFE from the IPF, which agrees the results of previous studies.\textsuperscript{22} This may delay diagnosis, as spirometry is the most easily accessible pulmonary function test.\textsuperscript{27}

Although some studies reported lower values of DLco in patients with CPFE compared to in IPF,\textsuperscript{24} including in our study and a study by Jacob et al\textsuperscript{28}, similar values were observed in both groups (IPF and CPFE). Interestingly, Kco was lower in the CPFE group. The coexistence of emphysema and fibrosis leads to normal or subnormal volumes and pulmonary fluxes, while DLco was substantially reduced.\textsuperscript{24,28}

SBWN\textsubscript{2} is an important tool for evaluating the homogeneity of alveolar ventilation and for the early detection of small airway changes in patients with COPD.\textsuperscript{5} The main parameters obtained by SBWN\textsubscript{2} are SIII and CV, which are directly correlated with FEV\textsubscript{1} and FVC in patients with COPD.\textsuperscript{5} SIII is characterized by changes in the N\textsubscript{2} concentration expired between 25\% and 75\% of the VC and $\Delta$N\textsubscript{2} 750–1250mL. Both parameters reflect the distribution of ventilation, ie, whether there is homogeneity in ventilation. CV is the portion of the VC that begins after the start of airway closure (phase IV) and affects the RV. In ordinary individuals, this value is <20\% of VC; higher values are observed in both obstructive and restrictive patients. The CC is the CV associated with RV.\textsuperscript{4}

No studies comparing SBWN\textsubscript{2} have been conducted in patients with IPF and CPFE. Silva et al. conducted SBWN\textsubscript{2} in patients with systemic sclerosis and pulmonary involvement and compared them with a healthy population. They found that SIII was the most sensitive pulmonary function alteration in these patients, even when other pulmonary function tests were normal.\textsuperscript{29}

The SBWN\textsubscript{2} test showed heterogeneity in pulmonary ventilation in all three conditions (IPF, CPFE and COPD), without large differences between groups, which did not aid in the functional differentiation between IPF and CPFE. Additionally, our data suggested that patients with CPFE experienced significant air trapping, even when the lung volumes were within normal limits. Patients included in our study had evident fibrosis in CT scanning. Thus, SBWN\textsubscript{2} may be a sensitive test for evaluating the progression of fibrosis in patients with initial fibrosing disease.

Periostin levels were significantly higher in the serum of the CPFE group than in the other two groups. Periostin is involved in processes that lead to pulmonary fibrosis formation and pulmonary remodeling, as well as in eosinophil recruitment and mucus production.\textsuperscript{6} Periostin has been evaluated in the context of pulmonary fibrosis and asthma, but a recently published study revealed no significant difference between the levels of periostin in asthma compared to in COPD.\textsuperscript{30} Several studies suggested that periostin
is a biomarker in patients with IPF, but no studies have evaluated periostin behaviour in CPFE. Caswell-Smith et al. reported reference values for periostin in adults without asthma and no COPD at 50 ng/mL. In our study, only the CPFE group showed values higher than the reference. As this biomarker may be increased in both fibrosis and COPD, it is possible that the association of the two changes contributed to the outstanding increase in patients with CPFE.

Mucin-16 (MUC16 or CA-125) is a tumor biomarker widely evaluated in medical practice and is mainly related to gynecological tumors, such as those in the ovaries. However, some authors observed increased levels (>35 U/mL) in patients with interstitial lung diseases, particularly IPF, even suggesting a worse prognosis with increased mortality and increased risk of lung cancer. We found that patients with IPF had higher levels of mucin-16 than patients with CPFE. This may be related to the fibrosis degree. One hypothesis to explain this results is that the presence of emphysema reduces lung density, as mucin-16 is present on the pulmonary epithelial surface.

PDGF-BB and TGF-β1 have been proposed as biomarkers for differentiating between IPF and CPFE. These molecules participate in collagen formation and complement system regulation and may help in this differentiation; however, the data revealed no significant difference in PDGF-BB and TGF-β1 among the three groups.

Because of the cross-sectional design of the study, the prognostic role of these functional and biochemical markers could not be assessed. Another limitation of this study was that the study was conducted in a single center and included only patients with an evident UIP pattern, and it was not possible to evaluate whether the observed changes also occurred in patients with incipient lesions. In addition, the lack of a control group with healthy patients may be a limiting factor. However, this study provides insight useful for future studies that include patients with IPF and CPFE.

Conclusions

SBWN$_2$ is an easy test to perform and may assist in the differential diagnosis of IPF and CPFE. Additionally, periostin appears to be an important biomarker for differentiating CPFE from IPF, just as mucin-16 appears to be related to IPF. These data suggest that CFPE has distinct functional and serologic characteristics from isolated IPF.

List Of Abbreviations

CC: Closing capacity
CO: Carbon monoxide
COPD: Chronic obstructive pulmonary disease
CPFE: Combined pulmonary fibrosis and emphysema
CV: Closing volume

DLco: Carbon monoxide diffusion capacity

ELISA: Enzyme-linked immunosorbent assay

FEV$_1$: Forced expiratory volume in the first second

FVC: Forced vital capacity

GOLD: Global Initiative for Chronic Obstructive Lung Disease

HRCT: High resolution chest computed tomography

ILD: Interstitial lung disease

IPF: Idiopathic pulmonary fibrosis

IQR: interquartile range

Kco: Transfer coefficient

MDD: Multidisciplinary discussion

mMRC: Modified Medical Research Council

MUC–16: Mucin–16

PDGF-BB: Platelet-derived growth factor-BB

RV: Residual volume

SIII: Phase III slope

SBWN$_2$: Single-maneuver nitrogen washout test

TGF-$\beta_1$: Transforming growth factor

TLC: Total lung capacity

UIP: Usual interstitial pneumonia

VC: vital capacity

References
1. Baddini-Martinez J, Baldi BG, Costa CH da, Jezler S, Lima MS, Rufino R. Update on diagnosis and treatment of idiopathic pulmonary fibrosis. J Bras Pneumol. 2015;41(5):454–66.
2. Cottin V, Nunes H, Brillet P-Y, Delaval P, Devouassoux G, Tillie-Leblond I, et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J. 2005 Oct;26(4):586–93.
3. Jankowich MD, Rounds SIS. Combined Pulmonary Fibrosis and Emphysema Syndrome [Internet]. Vol. 141, Chest. 2012. p. 222–31. Available from: http://dx.doi.org/10.1378/chest.11–1062
4. Lopes, AJ. A retomada do teste do washout do nitrogênio na prática pneumológica. Pulmão RJ. 2015; 24(1):14–18.
5. Mikamo M, Shirai T, Mori K, Shishido Y, Akita T, Morita S, et al. Predictors of phase III slope of nitrogen single-breath washout in COPD. Respir Physiol Neurobiol. 2013 Oct 1;189(1):42–6.
6. O’Dwyer DN, Moore BB. The role of periostin in lung fibrosis and airway remodeling. Cell Mol Life Sci. 2017 Dec;74(23):4305–14.
7. Neighbors M, Cabanski CR, Ramalingam TR, Sheng XR, Tew GW, Gu C, et al. Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials. The Lancet Respiratory Medicine. 2018 Aug;6(8):615–26.
8. Tajiri M, Okamoto M, Fujimoto K, Johkoh T, Ono J, Tominaga M, et al. Serum level of periostin can predict long-term outcome of idiopathic pulmonary fibrosis [Internet]. Vol. 53, Respiratory Investigation. 2015. p. 73–81. Available from: http://dx.doi.org/10.1016/j.resinv.2014.12.003
9. Gu H, Mickler EA, Cummings OW, Sandusky GE, Weber DJ, Gracon A, et al. Crosstalk between TGF-β1 and complement activation augments epithelial injury in pulmonary fibrosis. FASEB J. 2014 Oct;28(10):4223–34.
10. Aono Y, Kishi M, Yokota Y, Azuma M, Kinoshita K, Takezaki A, et al. Role of platelet-derived growth factor/platelet-derived growth factor receptor axis in the trafficking of circulating fibrocytes in pulmonary fibrosis. Am J Respir Cell Mol Biol. 2014 Dec;51(6):793–801.
11. Hostettler KE, Zhong J, Papakonstantinou E, Karakiulakis G, Tamm M, Seidel P, et al. Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis. Respir Res. 2014 Dec 12;15:157.
12. Dai H, Liu J, Liang L, Ban C, Jiang J, Liu Y, et al. Increased lung cancer risk in patients with interstitial lung disease and elevated CEA and CA125 serum tumour markers. Respirology. 2014 Jul;19(5):707–13.
13. Maher TM, Oballa E, Simpson JK, Porte J, Habgood A, Fahy WA, et al. An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study. Lancet Respir Med. 2017 Dec;5(12):946–55.
14. Raghu G. Idiopathic pulmonary fibrosis: guidelines for diagnosis and clinical management have advanced from consensus-based in 2000 to evidence-based in 2011 [Internet]. Vol. 37, European Respiratory Journal. 2011. p. 743–6. Available from: http://dx.doi.org/10.1183/09031936.00017711
15. GOLD (Global Initiative for Chronic Obstructive Lung Disease) 2017 [Internet]. Vol. 71, Pneumologie. 2017. p. 9–14. Available from: http://dx.doi.org/10.1555/s-0042–121903
16. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005 Aug;26(2):319–38.
17. Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis. 1983 Jun;127(6):725–34.
18. Neder JA, Andreoni S, Castelo-Filho A, Nery LE. Reference values for lung function tests: I. Static volumes [Internet]. Vol. 32, Brazilian Journal of Medical and Biological Research. 1999a. p. 703–17. Available from: http://dx.doi.org/10.1590/s0100–879x1999000600006
19. Neder JA, Andreoni S, Peres C, Nery LE. Reference values for lung function tests: III. Carbon monoxide diffusing capacity (transfer factor) [Internet]. Vol. 32, Brazilian Journal of Medical and Biological Research. 1999b. p. 729–37. Available from: http://dx.doi.org/10.1590/s0100–879x1999000600008
20. Robinson PD, Latzin P, Verbanck S, Hall GL, Horsley A, Gappa M, et al. Consensus statement for inert gas washout measurement using multiple- and single-breath tests. Eur Respir J. 2013 Mar;41(3):507–22.
21. Buist AS, Ross BB. Predicted values for closing volumes using a modified single breath nitrogen test. Am Rev Respir Dis. 1973 May;107(5):744–52.
22. Cottin V. Combined pulmonary fibrosis and emphysema: bad and ugly all the same? Eur Respir J 2017;50: 1700846; DOI: 10.1183/13993003.00846–2017
23. Cottin V, Nunes H, Mouthon L, Gamondes D, Lazor R, Hachulla E, et al. Combined pulmonary fibrosis and emphysema syndrome in connective tissue disease. Arthr Rheum 2011 Jan;63(1):295–304.
24. Papiris SA, Triantafflidou C, Manali ED, et al. Combined pulmonary fibrosis and emphysema. Expert Rev Respir Med 2013;7: 19–31
25. Marten K, Milne D, Antoniou KM, et al. Non-specific interstitial pneumonia in cigarette smokers: a CT study. Eur Radiol 2009;19:1679–1685.
26. Doherty MJ, Pearson MG, O'Grady EA, Pellegrini V, Calvery PC. Cryptogenic fibrosing alveolitis with preserved lung volumes. Thorax 1997;52:998–100.
27. Dias OM, Baldi BG, Costa AN, Carvalho CRR. Combined pulmonary fibrosis and emphysema: an increasingly recognized condition. J Bras Pneumol. 2014 May;40(3):304–12.
28. Jacob J, Bartholmai BJ, Rajagopalan S, Kokosi M, Maher TM, Nair A, et al. Functional and prognostic effects when emphysema complicates idiopathic pulmonary fibrosis. Eur Respir J [Internet]. 2017 Jul;50(1). Available from: http://dx.doi.org/10.1183/13993003.00379–2017
29. Silva BRA, Rufino R, Costa CH, Vilela VS, Levy RA, Lopes AJ. Ventilation distribution and small airway function in patients with systemic sclerosis. Rev Port Pneumol. 2017 May;23(3):132–8.
30. Katoh S, Ikeda M, Shirai R, Abe M, Ohue Y, Kobashi Y, et al. Biomarkers for differentiation of patients with asthma and chronic obstructive pulmonary disease. J Asthma. 2018 Oct;55(10):1052–8.
31. Caswell-Smith R, Hosking A, Cripps T, Holweg C, Matthews J, Holliday M, et al. Reference ranges for serum periostin in a population without asthma or chronic obstructive pulmonary disease [Internet]. Vol. 46, Clinical & Experimental Allergy. 2016. p. 1303–14. Available from: http://dx.doi.org/10.1111/cea.12763

**Declarations**

**Ethics approval and consent to participate**

This study was approved by the Research Ethics Committee of the Pedro Ernesto University Hospital, State University of Rio de Janeiro.

**Consent for publication**

All research subjects signed and obtained a copy of the Free and Informed Consent Form.

**Availability of data and materials**

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request. All data generated or analysed during this study are included in this published article.

**Competing interests**

The authors declare that they have no competing interests in this section.

**Funding**

This work was supported by Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro – FAPERJ.

**Authors’ contributions**

FMA did the historical reference, collected the data, analyzed and interpreted the data and wrote the article. CHC assisted in the historical framework, in the analysis and interpretation of data and in the writing of the article. LSR, TPA, MMA and MCBSL performed the analysis of laboratory tests. LFF and TFC assisted in data collection. AGL and RLR assisted in the analysis and interpretation of the data.

**Acknowledgements**

Not applicable.

**Figures**
Figure 1: Flow diagram design

(*) After MDD, cases recommended to biopsy or suggestive of an alternative diagnosis were excluded. Only cases with tomographic UIP pattern and a firm diagnosis of IPF and CPFE were included.

ILD: interstitial lung disease, MDD: multidisciplinary discussion, IPF: idiopathic pulmonary fibrosis; CPFE: combined pulmonary fibrosis and emphysema; COPD: chronic obstructive pulmonary disease, DLco: Carbon monoxide diffusion capacity

Figure 1

Flow diagram design
Figure 2

Serum biomarkers evaluated in patients with IPF, CFPE and COPD. Circulating levels of periostin (A), mucin-16 (B), PDGF-BB (C) and TGF-β1 (D) from patients diagnosed with pulmonary emphysema, CPFE and IPF. The biomarkers were measured in sera of patients using ELISA. *p < 0.05; **p < 0.001. CPFE: combined pulmonary fibrosis and emphysema; IPF: idiopathic pulmonary fibrosis.